At Insmed we are on a mission to transform the lives of patients battling serious rare diseases. We are developing novel, targeted therapies to help serve the critical unmet needs of these patients. In concert with developing therapeutic solutions, we are committed to improving the entire patient experience, from diagnosis and treatment to everyday living.
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Wed, 22 Nov 2017 21:30:00 +0000 BRIDGEWATER, N.J., Nov. 22, 2017-- Insmed Incorporated, a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced the granting of inducement awards to ...
See what the IHS Markit Score report has to say about Insmed Inc. Wed, 22 Nov 2017 13:02:21 +0000 The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
3 Companies Spearheading the Antibiotics Space in 2018 Fri, 10 Nov 2017 16:15:32 +0000 Thanks to progress made in 2017 though, it looks like 2018 could see both a radically new way of delivering antibiotics and finally the first new class approved in 30 years. Here are three companies involved ...
Insmed to Present at Two November Conferences Wed, 08 Nov 2017 21:30:00 +0000 BRIDGEWATER, N.J., Nov. 08, 2017-- Insmed Incorporated, a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced that Will Lewis, President and Chief ...
Insmed reports 3Q loss Thu, 02 Nov 2017 12:03:42 +0000 On a per-share basis, the Bridgewater, New Jersey-based company said it had a loss of 69 cents. The results matched Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...
Insmed Reports Third Quarter 2017 Financial Results and Provides Business Update Thu, 02 Nov 2017 11:30:00 +0000 During the third quarter, the Company announced positive top-line results from its Phase 3 CONVERT Study of ALIS in patients with NTM lung disease caused by MAC, a rare, progressive, destructive lung infection ...
Insmed Incorporated to Host Earnings Call Thu, 02 Nov 2017 10:20:00 +0000 NEW YORK, NY / ACCESSWIRE / November 2, 2017 / Insmed Incorporated (NASDAQ: INSM ) will be discussing their earnings results in their Q3 Earnings Call to be held on November 2, 2017 at 8:30 AM Eastern ...
*Winners defined as our Top Picks that increased 20% or more within a 6-month period.
Red Letters imply that that particular criteria did not meet minimum requirements, e.g., a low GSA Rank would show it in red.
___ Red Line On Graph Shows a Trailing Stop Loss Based on Support and Resistance Levels. See how it works.
___ Blue Line On Graph Shows the 10-Week Moving Average.
___ Magenta Line On Graph Shows the 40-Week Moving Average.
Disclaimer The stock selections in our stock investing and stock trading database are not stock recommendations, but simply represent applications of a stock investing process. All materials, including our Top Stock Picks, are provided for information purposes only and should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security. Growth Stock Analytics, LLC is not responsible for gains/losses that may result in investing or trading in these securities. All information is believed to be obtained from reliable sources, but there is no guarantee that the information supplied is accurate, complete or timely. There is no guarantee or warranty with regard to the results obtained from its use. There is no guarantee of suitability or potential value of any particular investment or information source. You acknowledge that your requests for this information are unsolicited and shall neither constitute nor be considered investment advice. Past investing performance is not an indication of future performance results. Investing and trading in stocks is risky. Investors are encouraged to consult a registered stock broker or investment adviser before making any investing decisions. The interpretations and opinions expressed herein are solely those of Growth Stock Analytics, LLC, and not of any other individual or organization.